Blocking PD-L2-RGMb interactions or deleting RGMb in T cells significantly restored anti-PD-1 responsiveness in previously resistant models, including germ-free mice and fecal microbiota-transplanted mice, indicating microbiota-driven remodeling of the tumor immune microenvironment (TIM) (105). The gene discussed is PDCD1; the disease is neoplasm.